Navigation Links
Factor Bioscience Granted First U.S. Patent for RNA-Based Reprogramming Technology
Date:7/31/2013

CAMBRIDGE, Mass., July 31, 2013 /PRNewswire/ -- The United States Patent and Trademark Office today granted Factor Bioscience the first patent covering methods for reprogramming cells using RNA, a technology with wide-ranging applications in biological research and personalized medicine. The patented methods can transform patient skin cells into stem cells more rapidly, efficiently, and safely than previous techniques.

"Reprogramming is an amazing process, when it works," explains co-inventor Dr. Christopher Rohde, Chief Operating Officer and Director of High-Throughput Technologies. "However, previous methods were burdened by cumbersome protocols, poor reliability, and woeful inefficiency. Our RNA-reprogramming technology overcomes all of these limitations while being faster and safer than the best available techniques."

Excitement has been growing in the reprogramming field since Dr. Shinya Yamanaka's Nobel Prize-winning discovery in 2006 that infecting skin cells with a specific combination of viruses could reprogram them to a pluripotent stem-cell state. However, efforts to achieve the same goal without using the potentially mutation-causing viruses had, until this point, yielded mixed results. "Many researchers have attempted to develop a reliable DNA-free reprogramming method, and more than one have claimed success," says co-inventor Dr. Matt Angel, CEO. "In every case, the reported method turned out to be unreliable at best, and more often than not, completely irreproducible. The grant of the first patent covering reliable DNA-free reprogramming technology brings us one step closer to the development of therapeutics based on safely reprogrammed cells."

The methods developed by Dr. Angel's team can be used with a wide range of reprogramming factors and cell types, and the company is making chemically-defined, animal component-free versions of its products available for therapeutic applications. Dr. Angel's goal is to deploy the technology as widely as possible through a combination of products, services, and partnerships. "Factor Bioscience is a unique company, owned and operated entirely by scientists. The development of the first reliable RNA-reprogramming technology is the perfect example of what is possible in this environment."

About Factor Bioscience
Founded in 2011, Factor Bioscience develops nucleic-acid and cell-based research tools and therapeutics using its patented and patent-pending reprogramming and gene-editing technologies. For more information, visit www.factorbio.com, and follow us on Twitter at @factorbio.

The content of this press release is the sole responsibility of the authors and does not necessarily represent the official views of the USPTO.


'/>"/>
SOURCE Factor Bioscience
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Elsevier Announces 2012 Journal Impact Factor Highlights
2. Closed Drug Transfer Systems: Oncology Therapeutics Market Dynamics and Closed Drug Transfer Design Factors - Market Forecasts to 2017
3. Latest Cell Publication of OriGene and Peking University Collaborative Discovery of New iPSC Reprogramming Factors
4. New study identifies the role of a key growth factor in promoting formation of hair follicles and suggests a new therapeutic approach to treat baldness
5. Cell Culture Market (Media, Sera, Reagents, Serum-Free Media, Albumin, Growth Factors & Cytokines, Instruments, Bioreactors, Roller Bottle Equipment, T-Flasks And Cryostorage Equipment) - Global Industry Analysis, Size, Share, Growth, Trends And For
6. Researchers identify transcription factors that regulate retinal vascularization
7. ChemAxon Provides Chemistry Informatics Platform for the European Lead Factory
8. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
9. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
10. CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat hemophilia B
11. The X factor in liver metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of ... board-certified in surgery and surgery of the hand by the National Board of ... to going above and beyond in his pursuit of providing the most comprehensive, ...
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority ... announced that Charles W. Stellar has been named by the WEDI Board of Directors ... 2016. As an executive leader with more than 35 years of experience in healthcare, ...
(Date:5/24/2016)... Mass. (PRWEB) , ... May 24, 2016 , ... ... heart attacks, diabetes, and traumatic injuries, will be accelerated by research at Worcester ... cells into engines of wound healing and tissue regeneration. , The novel method, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Media ... The new Media Cybernetics corporate branding reflects a results-driven revitalization for a company ... analysis. The re-branding components include a crisp, refreshed logo and a new web ...
Breaking Biology Technology:
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/18/2016)... --> --> Competitive Landscape ... Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which is ... & security companies in the border security market and ...
(Date:3/15/2016)... March 15, 2016 Yissum Research Development ... technology-transfer company of the Hebrew University, announced today the ... sensing technology of various human biological indicators. Neteera Technologies ... million from private investors. ... the detection of electromagnetic emissions from sweat ducts, enables ...
Breaking Biology News(10 mins):